FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress
Roberto Ronca1, Gaia C Ghedini1, Federica Maccarinelli1
1Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Abstract:
Multiple myeloma, the second most common hematologic malignancy, frequently relapses because of chemotherapeutic resistance. Fibroblast growth factors (FGF) act as proangiogenic and mitogenic cytokines in multiple myeloma. Here, we demonstrate that the autocrine FGF/FGFR axis is essential for multiple myeloma cell survival and progression by protecting multiple myeloma cells from oxidative stress-induced apoptosis. In keeping with the hypothesis that the intracellular redox status can be a target for cancer therapy, FGF/FGFR blockade by FGF trapping or tyrosine kinase inhibitor impaired the growth and dissemination of multiple myeloma cells by inducing mitochondrial oxidative stress, DNA damage, and apoptotic cell death that were prevented by the antioxidant vitamin E or mitochondrial catalase overexpression. In addition, mitochondrial oxidative stress occurred as a consequence of proteasomal degradation of the c-Myc oncoprotein that led to glutathione depletion. Accordingly, expression of a proteasome-nondegradable c-Myc protein mutant was sufficient to avoid glutathione depletion and rescue the proapoptotic effects due to FGF blockade. These findings were confirmed on bortezomib-resistant multiple myeloma cells as well as on bone marrow-derived primary multiple myeloma cells from newly diagnosed and relapsed/refractory patients, including plasma cells bearing the t(4;14) translocation obtained from patients with high-risk multiple myeloma. Altogether, these findings dissect the mechanism by which the FGF/FGFR system plays a nonredundant role in multiple myeloma cell survival and disease progression, and indicate that FGF targeting may represent a therapeutic approach for patients with multiple myeloma with poor prognosis and advanced disease stage. SIGNIFICANCE: This study provides new insights into the mechanisms by which FGF antagonists promote multiple myeloma cell death. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/11/2340/F1.large.jpg.
Insights
Fibroblast growth factor (FGF) signaling is crucial for multiple myeloma cell survival. Blocking FGF/FGFR pathways induces oxidative stress and apoptosis, offering a potential therapeutic strategy for resistant and high-risk multiple myeloma.
Area of Science:
- Hematologic Malignancies
- Cancer Biology
- Molecular Oncology
Background:
- Multiple myeloma (MM) is the second most common hematologic malignancy, often characterized by relapse due to chemotherapeutic resistance.
- Fibroblast growth factors (FGF) and their receptors (FGFR) are implicated as proangiogenic and mitogenic factors in MM progression.
Purpose of the Study:
- To investigate the role of the autocrine FGF/FGFR axis in MM cell survival and progression.
- To explore the potential of targeting the FGF/FGFR axis as a therapeutic strategy for MM, particularly in resistant cases.
Main Methods:
- Utilized FGF trapping and tyrosine kinase inhibitors to block FGF/FGFR signaling in MM cells.
- Assessed the impact of FGF/FGFR blockade on oxidative stress, DNA damage, apoptosis, and c-Myc oncoprotein levels.
- Investigated the role of proteasomal degradation and glutathione depletion in the observed effects.
- Validated findings in bortezomib-resistant MM cells and primary patient samples, including high-risk MM.
Main Results:
- The autocrine FGF/FGFR axis is essential for MM cell survival, protecting against oxidative stress-induced apoptosis.
- FGF/FGFR blockade induces mitochondrial oxidative stress, DNA damage, and apoptosis, which can be rescued by antioxidants.
- Proteasomal degradation of c-Myc leads to glutathione depletion and sensitizes MM cells to FGF blockade.
- Targeting FGF/FGFR is effective in bortezomib-resistant MM and primary patient cells, including those with high-risk translocations.
Conclusions:
- The FGF/FGFR system plays a critical, nonredundant role in MM cell survival and disease progression.
- FGF/FGFR blockade represents a promising therapeutic strategy for patients with poor prognosis and advanced-stage multiple myeloma.
- Understanding the interplay between FGF/FGFR signaling, oxidative stress, and c-Myc is key to developing novel MM therapies.
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle


